Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 2Breast 1

Conditions

Neoplasm Metastasis 1Breast Neoplasms, Male 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Trastuzumab 18Radiosurgery 15Capecitabine 13Lapatinib 11Radiotherapy 9Magnetic Resonance Spectroscopy 9trastuzumab deruxtecan 7Temozolomide 6tucatinib 4pembrolizumab 4paclitaxel-Angiopep-2 conjugate 4eribulin 4Vinorelbine 4Specimen Handling 4Paclitaxel 4Methotrexate 4Cisplatin 4sacituzumab govitecan 3pyrotinib 3abemaciclib 3Radiation 3Fluorodeoxyglucose F18 3pertuzumab 2palbociclib 2neratinib 2durvalumab 2cediranib 2cabazitaxel 2Sodium Chloride 2Observation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Brain Neoplasms × peginterferon alfa-2a × Breast × Clear all
NCT00227656 2012-12-11

Capecitabine and Pegylated Interferon Alfa-2a in Treating Patients With Recurrent or Progressive Brain Metastases Due to Breast Cancer

M.D. Anderson Cancer Center

Phase 2 Terminated
2 enrolled
BreastCNS

Brain Neoplasms, Breast Neoplasms, Neoplasm Metastasis, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡